Logo image of BYSI

BEYONDSPRING INC (BYSI) Stock Fundamental Analysis

NASDAQ:BYSI - Nasdaq - KYG108301006 - Common Stock - Currency: USD

1.79  +0.07 (+4.07%)

After market: 1.75 -0.04 (-2.23%)

Fundamental Rating

1

Overall BYSI gets a fundamental rating of 1 out of 10. We evaluated BYSI against 571 industry peers in the Biotechnology industry. BYSI may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, BYSI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BYSI has reported negative net income.
In the past 5 years BYSI always reported negative net income.
BYSI had a negative operating cash flow in each of the past 5 years.
BYSI Yearly Net Income VS EBIT VS OCF VS FCFBYSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of BYSI (-100.62%) is worse than 76.55% of its industry peers.
Industry RankSector Rank
ROA -100.62%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BYSI Yearly ROA, ROE, ROICBYSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BYSI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BYSI Yearly Profit, Operating, Gross MarginsBYSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10K -20K -30K

More info and screens

1

2. Health

2.1 Basic Checks

BYSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BYSI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BYSI Yearly Shares OutstandingBYSI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
BYSI Yearly Total Debt VS Total AssetsBYSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -29.37, we must say that BYSI is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BYSI (-29.37) is worse than 90.76% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -29.37
ROIC/WACCN/A
WACC9.44%
BYSI Yearly LT Debt VS Equity VS FCFBYSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

A Current Ratio of 1.82 indicates that BYSI should not have too much problems paying its short term obligations.
BYSI has a Current ratio of 1.82. This is in the lower half of the industry: BYSI underperforms 78.86% of its industry peers.
BYSI has a Quick Ratio of 1.82. This is a normal value and indicates that BYSI is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.82, BYSI is not doing good in the industry: 77.09% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.82
BYSI Yearly Current Assets VS Current LiabilitesBYSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.57% over the past year.
The Revenue has grown by 29.70% in the past year. This is a very strong growth!
Measured over the past years, BYSI shows a very strong growth in Revenue. The Revenue has been growing by 113.47% on average per year.
EPS 1Y (TTM)36.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.05%
Revenue 1Y (TTM)29.7%
Revenue growth 3Y113.47%
Revenue growth 5YN/A
Sales Q2Q%14.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-138.3%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BYSI Yearly Revenue VS EstimatesBYSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
BYSI Yearly EPS VS EstimatesBYSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BYSI. In the last year negative earnings were reported.
Also next year BYSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BYSI Price Earnings VS Forward Price EarningsBYSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BYSI Per share dataBYSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BYSI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEYONDSPRING INC

NASDAQ:BYSI (2/21/2025, 8:04:49 PM)

After market: 1.75 -0.04 (-2.23%)

1.79

+0.07 (+4.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2024-05-01/amc
Earnings (Next)N/A N/A
Inst Owners13.09%
Inst Owner Change-99.78%
Ins Owners21.3%
Ins Owner Change0%
Market Cap72.14M
Analysts85.71
Price TargetN/A
Short Float %6.52%
Short Ratio91.61
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 41.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.04
BVpS-0.75
TBVpS-0.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.82
Altman-Z -29.37
F-ScoreN/A
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)1593.16%
Cap/Depr(5y)968.4%
Cap/Sales(3y)72.77%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.05%
EPS Next Y-138.3%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)29.7%
Revenue growth 3Y113.47%
Revenue growth 5YN/A
Sales Q2Q%14.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y41.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.48%
OCF growth 3YN/A
OCF growth 5YN/A